We are live on ! Find out more
CG

Column Group Portfolio holdings

AUM $88.1M
1-Year Est. Return 148.03%
This Fund
S&P 500
This Quarter Est. Return
+37.58%
1 Year Est. Return
+148.03%
3 Year Est. Return
+95.12%
5 Year Est. Return
+23.89%
10 Year Est. Return
–
AUM
$151M
AUM Growth
+$769K
Cap. Flow
-$32M
Cap. Flow %
-21.13%
Top 10 Hldgs %
100%
Holding
7
New
–
Increased
–
Reduced
2
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$29.6M
2
EFTR
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
+$2.42M
3
SRZN icon
Surrozen
SRZN
+$14

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RAPT
1
DELISTED
RAPT Therapeutics
RAPT
$66.6M 44%
335,078
– –
ORIC icon
2
Oric Pharmaceuticals
ORIC
$1.44B
$32.8M 21.69%
3,568,181
– –
TNYA icon
3
Tenaya Therapeutics
TNYA
$163M
$30.5M 20.12%
9,400,290
– –
NGM
4
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$15.6M 10.29%
18,136,735
– –
SRZN icon
5
Surrozen
SRZN
$282M
$5.9M 3.9%
627,651
-2
-0% -$14
RVMD icon
6
Revolution Medicines
RVMD
$43.7B
$1.32K ﹤0.01%
46
-1,230,595
-100% -$29.6M
EFTR
7
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
– –
-161,049
Closed -$2.42M

Similar funds

PIS
POM Investment Strategies Raleigh, North Carolina $88.3M AUM 15.23% 1-Year Est. Return
FWM
FSR Wealth Management Elmhurst, Illinois $87.8M AUM 10.63% 1-Year Est. Return
WP
Walleye Partners Madison, Wisconsin $87.7M AUM
SHCM
Stone House Capital Management Bay Harbor Islands, Florida $88.5M AUM 149.16% 1-Year Est. Return
YIM
Yoffe Investment Management Lemoyne, Pennsylvania $87.4M AUM 30.8% 1-Year Est. Return
VPW
Variant Private Wealth Tysons, Virginia $88.9M AUM 25.07% 1-Year Est. Return
LC
Luminist Capital Grand Rapids, Michigan $89M AUM 17.66% 1-Year Est. Return
BI
Bradyco Inc Cambridge, Massachusetts $87.2M AUM 8.85% 1-Year Est. Return

Column Group's Q4 2023 Portfolio in Review

As of Q4 2023, Column Group held 7 positions worth $151M, up 0.51% from $151M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Column Group withdrew a net $32M in Q4 2023, closing 1 position and reducing 2 holdings. Its most notable exit was eFFECTOR Therapeutics, Inc. Common Stock, an estimated $2.42M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Column Group's biggest Q4 2023 reduction was Revolution Medicines, cutting an estimated $29.6M.
  • Column Group fully exited eFFECTOR Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $2.42M.
  • Column Group's ten largest holdings make up 100% of its $151M portfolio in Q4 2023.
  • Column Group opened 0 new positions and closed 1 in Q4 2023.
  • Column Group's portfolio value rose 0.51% quarter-over-quarter to $151M.

Based on Column Group's 13F filing for Q4 2023, filed 9 Feb 2024.